SCHEMBL6317875

SCHEMBL6317875

CC(NC(=O)c1c(-c2coc3ccccc23)noc1N)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.52
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 7/20 0.43
LMNA P02545 3/20 0.43
THRB P10828 2/20 0.43
KDM4E B2RXH2 1/20 0.42
POLB P06746 2/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 1/20 0.40
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324816 0.89 ALDH1A1 (0.44) L3MBTL1ALDH1A1HTT
SCHEMBL6323394 0.87 L3MBTL1 (0.37) L3MBTL1KMT2AALDH1A1LMNA
SCHEMBL6316505 0.85 RAB9A (0.42) L3MBTL1KMT2AMEN1ALDH1A1LMNA
SCHEMBL6323271 0.84 ACACB (0.37) L3MBTL1KMT2AMEN1POLB
SCHEMBL6324905 0.84 TAS1R3 (0.42) L3MBTL1ALDH1A1LMNAHTTNPSR1
SCHEMBL6321748 0.84 TACR3 (0.42) ALDH1A1HTTSMN1; SMN2
SCHEMBL6317238 0.84 L3MBTL1 (0.44) L3MBTL1KMT2AALDH1A1LMNATHRB
SCHEMBL6323650 0.83 KMT2A (0.47) KMT2AMEN1ALDH1A1LMNAPOLB
SCHEMBL6617822 0.83 MAOB (0.37) L3MBTL1KMT2AALDH1A1LMNAKDM4E
SCHEMBL6323089 0.83 NPC1 (0.44) L3MBTL1KMT2AMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 L3MBTL1 4176/4885KMT2A 1089/4885MEN1 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.